Abstract Background and Aims The association between tumour necrosis factor inhibitors
[TNFi] and malignancy in patients with inflammatory bowel disease [IBD] is not well …

There have been increasing concerns regarding the safety of perioperative anti-tumour
necrosis factor (anti-TNF) α agents. We performed a literature review to evaluate the post …

Background: Several placebo controlled studies have demonstrated the efficacy of infliximab
in inflammatory bowel disease (IBD) but the potential toxicity of this new biological …

Background & Aims We performed a systematic review and meta-analysis to evaluate the
comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF …

Abstract Background and Aims The combination of infliximab and azathioprine is more
efficacious than either therapy alone for Crohn's disease [CD] and ulcerative colitis [UC] …

Background Tumour necrosis factor (TNF)‐alpha inhibitors are a major advance in the
management of inflammatory bowel disease but increase the risk for tuberculosis (TB). Aim …

The antitumour necrosis factor (TNF) medications, adalimumab and infliximab, play an
important role in the management of both Crohn's disease and ulcerative colitis. For those in …

Background: Discontinuation of anti-TNF therapy in patients with inflammatory bowel
diseases (IBD) in remission remains a controversial issue. The aims of our study were to …

Current therapy of moderate-to-severe inflammatory bowel disease (IBD) often involves the
use of anti-tumor necrosis factor alpha (TNF-α) agents. Although very effective, theses …

Background & Aims: Infliximab is effective for the treatment of active Crohn's disease.
However, rare but serious complications related to infliximab therapy including lymphoma …